The Regulation of Survivin Expression in Rectal Cancers during preoperative Radiochemotherapie and its Impact on Recurrence and Survival

Thilo Sprenger, Franz Rödel, Tim Beissbarth, Lena Conradi, B. Michael Ghadimi, Heinz Becker, Claus Rödel & Torsten Liersch
Introduction: Valid molecular markers need to be implemented in clinical trials to fulfill the demand of a risk-adapted and more individualized multimodal therapy of locally advanced primary rectal cancer. In the present study the expression of the inhibitor-of-apoptosis (IAP) protein Survivin was evaluated[for full text, please go to the a.m. URL]